USPTO serial 98173706
ANIVIO
Reviewed by CopyMark Law Group
Status 731Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- SMITH, BRENDAN K
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with ANIVIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*
Plus Government fees of $450
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Eric R. Moran
Eric R. Moran MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP300 SOUTH WACKER DRIVE31ST FLOORCHICAGO, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; anti-TNF alpha antibodies for medical purposes; monoclonal antibodies for medical purposes; anti-inflammatories; anti-inflammatory biologic, biosimilar, and pharmaceutical preparations, namely, anti-inflammatory preparations; biologic, biosimilar, and pharmaceutical preparations for the treatment of lung diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of inflammatory disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of pulmonary sarcoidosis; biologic, biosimilar, and pharmaceutical preparations for the treatment of sarcoidosis; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent granulomas; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent fibrosis; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceutical preparations based on human monoclonal antibodies for the treatment of inflammatory diseases and disorders; pharmaceutical preparations containing self-replicating mRNA for the treatment of lung diseases and disorders, inflammatory disorders, pulmonary sarcoidosis, sarcoidosis; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent granulomas; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent fibrosis | ACTIVE | — |
| 042 | research and development of biologics, biosimilars, pharmaceuticals, and self-replicating mRNA; providing information in the field of scientific and medical research related to biologics, biosimilars, pharmaceuticals, and self-replicating mRNA | ACTIVE | — |
| 044 | providing medical information; providing health information | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Meitheal Pharmaceuticals, Inc.
- Other trademarks owned by Meitheal Pharmaceuticals, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ANIVIO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 8, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 7, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 7, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 7, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 8, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 7, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 7, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 7, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 7, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 12, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 12, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 6, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 8, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 11, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 11, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 11, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Feb 25, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Feb 25, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Dec 11, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Dec 11, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 11, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 6, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 6, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 6, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 6, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Aug 6, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| May 6, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 6, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 6, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 6, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 1, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 14, 2023 | NWAP | NEW APPLICATION ENTERED | — |